Online inquiry

IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6817MR)

This product GTTS-WQ6817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets STEAP1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012449.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26872
UniProt ID Q9UHE8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6817MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13468MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ871MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ3536MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ3957MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ3718MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ8941MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ9764MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ1350MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW